Current salivary biomarkers for detection of human papilloma virus‐induced oropharyngeal squamous cell carcinoma

Smith, Drew; Raslan, Shahm; Samuels, Michael Α.; Iglesias, Thomas; Buitron, Isabella; Deo, Sapna K.; Daunert, Sylvia; Thomas, Giovana R.; Califano, Joseph A.; Franzmann, Elizabeth

doi:10.1002/hed.26830

Cited by 7 publications

(7 citation statements)

References 101 publications

(203 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…59 In a study led by Rooper et al 59 100% and specificities from 88% to 100%. 55 There are still some limitations regarding ISH. The current understanding of interpreting ISH signals lacks uniform agreement on established thresholds, which adds complexity to their interpretation compared to the more straightforward p16 IHC.…”

Section: Ish For Hpv Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management

Tran,

Sais,

Tran

2024

Journal of Medical Virology

View full text Add to dashboard Cite

Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high‐risk human papillomavirus (HR HPV), notably HPV16 and HPV18. HPV status guides treatment and predicts outcomes, with distinct molecular pathways in HPV‐driven HNSCC influencing survival rates. HNC incidence is rising globally, with regional variations reflecting diverse risk factors, including tobacco, alcohol, and HPV infection. Oropharyngeal cancers attributed to HPV have significantly increased, particularly in regions like the United States. The HPV16 genome, characterized by oncoproteins E6 and E7, disrupts crucial cell cycle regulators, including tumor protein p53 (TP53) and retinoblastoma (Rb), contributing to HNSCC pathogenesis. P16 immunohistochemistry (IHC) is a reliable surrogate marker for HPV16 positivity, while in situ hybridization and polymerase chain reaction (PCR) techniques, notably reverse transcription‐quantitative PCR (RT‐qPCR), offer sensitive HPV detection. Liquid‐based RT‐qPCR, especially in saliva, shows promise for noninvasive HPV detection, offering simplicity, cost‐effectiveness, and patient compliance. These molecular advancements enhance diagnostic accuracy, guide treatment decisions, and improve patient outcomes in HNC management. In conclusion, advances in HPV detection and molecular understanding have significant clinical management implications. Integrating these advancements into routine practice could ultimately improve patient outcomes.

show abstract

Section: Ish For Hpv Detectionmentioning

confidence: 99%

“…Of note, RISH signals were visualized at low to medium magnification in 97% of positive cases. Over the last decade, studies on RISH have shown excellent diagnostic performance, with sensitivities ranging from 87% to 100% and specificities from 88% to 100% 55 …”

Section: Human Papillomavirus (Hpv)‐driven Head and Neck Cancers (Hncs)mentioning

confidence: 99%

Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management

Tran,

Sais,

Tran

2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Saliva testing has demonstrated its applicability in different settings, for example, for detection of oral cancer such as squamous cell carcinoma [4], identification of infectious diseases (helicobacter pylori [5], hepatitis [6], papilloma virus [7], etc. ), hormone monitoring [8][9][10], and screening for chronic kidney disorders [11].…”

Section: Of 15mentioning

confidence: 99%

New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing

Foddai,

Radin,

Barinotti

et al. 2023

IJERPH

View full text Add to dashboard Cite

(1) Background: Immunological laboratory testing is known to be complex, and it is usually performed in tertiary referral centers. Many criticalities affect diagnostic immunological testing, such as limited availability, the need for specifically trained laboratory staff, and potential difficulties in collecting blood samples, especially in the most vulnerable patients, i.e., the elderly and children. For this reason, the identification of a new feasible and reliable methodology for autoantibody detection is urgently needed. (2) Methods: We designed a systematic review to investigate the available literature on the utilization of saliva samples for immunological testing. (3) Results: A total of 170 articles were identified. Eighteen studies met the inclusion criteria, accounting for 1059 patients and 671 controls. The saliva collection method was mostly represented by passive drooling (11/18, 61%), and the most frequently described methodology for antibody detection was ELISA (12/18, 67%). The analysis included 392 patients with rheumatoid arthritis, 161 with systemic lupus erythematosus, 131 with type 1 diabetes mellitus, 116 with primary biliary cholangitis, 100 with pemphigus vulgaris, 50 with bullous pemphigoids, 49 with Sjogren syndrome, 39 with celiac disease, 10 with primary antiphospholipid syndromes, 8 with undifferentiated connective tissue disease, 2 with systemic sclerosis, and 1 with autoimmune thyroiditis. The majority of the reviewed studies involved adequate controls, and saliva testing allowed for a clear distinction of patients (10/12 studies, 83%). More than half of the papers showed a correlation between saliva and serum results (10/18, 55%) for autoantibody detection, with varying rates of correlation, sensitivity, and specificity. Interestingly, many papers showed a correlation between saliva antibody results and clinical manifestations. (4) Conclusions: Saliva testing might represent an appealing alternative to serum-based testing for autoantibody detection, considering the correspondence with serum testing results and the correlation with clinical manifestations. Nonetheless, standardization of sample collection processing, maintenance, and detection methodology has yet to be fully addressed.

show abstract

“…Not only are biofluids a rich source of molecular proteins and peptides, but their collection is also relatively simple and minimally invasive. For instance, salivary biomarkers have been proposed to detect and monitor inflammatory and infectious diseases including chronic inflammatory disorders (e.g., inflammatory bowel and periodontal conditions) and sexually transmitted infections (e.g., HIV and HPV) ( 4 – 7 ). The diagnostic accuracy of molecular biomarkers, however, need to be rigorously established before they transition to the convenience of POC testing.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Accuracy of Liquid Biomarkers in Airway Diseases: Toward Point-of-Care Applications

et al. 2022

View full text Add to dashboard Cite

BackgroundLiquid biomarkers have shown increasing utility in the clinical management of airway diseases. Salivary and blood samples are particularly amenable to point-of-care (POC) testing due to simple specimen collection and processing. However, very few POC tests have successfully progressed to clinical application due to the uncertainty and unpredictability surrounding their diagnostic accuracy.ObjectiveTo review liquid biomarkers of airway diseases with well-established diagnostic accuracies and discuss their prospects for future POC applications.MethodologyA literature review of publications indexed in Medline or Embase was performed to evaluate the diagnostic accuracy of liquid biomarkers for chronic obstructive pulmonary disease (COPD), asthma, laryngopharyngeal reflux (LPR), and COVID-19.ResultsOf 3,628 studies, 71 fulfilled the inclusion criteria. Sputum and blood eosinophils were the most frequently investigated biomarkers for the management of asthma and COPD. Salivary pepsin was the only biomarker with a well-documented accuracy for the diagnosis of LPR. Inflammatory blood biomarkers (e.g., CRP, D-dimers, ferritin) were found to be useful to predict the severity, complications, and mortality related to COVID-19 infection.ConclusionMultiple liquid biomarkers have well-established diagnostic accuracies and are thus amenable to POC testing in clinical settings.

show abstract

Current salivary biomarkers for detection of human papilloma virus‐induced oropharyngeal squamous cell carcinoma

Cited by 7 publications

References 101 publications

Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management

Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management

New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing

Diagnostic Accuracy of Liquid Biomarkers in Airway Diseases: Toward Point-of-Care Applications

Contact Info

Product

Resources

About